Knowing stock market today at a glance

Capricor Plunges 10.04% on Q1 Loss, Revenue Drop

Mover TrackerThursday, May 15, 2025 5:56 am ET

1min read

On May 15, 2025, Capricor's stock experienced a significant drop of 10.04% in pre-market trading, reflecting investor concerns and market sentiment.

Capricor Therapeutics reported a widening net loss for the first quarter of 2025, primarily due to increased research and development expenses and strategic investments in manufacturing and clinical operations. The company's earnings per share (EPS) of -$0.53 missed analyst expectations of -$0.32, further contributing to the negative market reaction. Additionally, revenue for the quarter was reported at $0, a stark decline from $4.9 million in the same period last year.

Despite the challenging financial results, Cantor Fitzgerald maintained a buy rating on Capricor Therapeutics, indicating confidence in the company's long-term prospects. This rating suggests that the current market downturn may present a buying opportunity for investors who believe in the company's innovative pipeline and strategic investments.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.